Lv3
380 积分 2024-11-04 加入
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
18天前
已完结
A systematic review and meta-analysis comparing the cardiovascular effects of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 agonists in type 2 diabetes
2个月前
已完结
Cardiorenal effects of therapies for type 2 diabetes and obesity
2个月前
已关闭
SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria
2个月前
已完结
Comparative efficacy and safety of SGLT2 inhibitor class members in patients with heart failure and type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials
2个月前
已完结
SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria
2个月前
已完结
Sodium-glucose cotransporter 2 inhibitors benefit to kidney and cardiovascular outcomes for patients with type 2 diabetes mellitus and chronic kidney disease 3b-4: A systematic review and meta-analysis of randomized clinical trials
2个月前
已完结
SGLT2 inhibitors in heart failure and chronic kidney disease: a systematic review
2个月前
已完结
SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria
2个月前
已完结
The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta-analysis
2个月前
已完结
皖公网安备34019202002308
